What is the clinical evidence from this study?

Study design: RCT. Population: chronic heart failure (n=48). Intervention: sildenafil vs. placebo. Primary outcome: change in flow-mediated vasodilation after release of 1, 3 and 5 min of transient arterial occlusion (p=< 0.05).

What question did this study set out to answer?

To determine the effects of sildenafil, a type 5 phosphodiesterase inhibitor, on flow-mediated vasodilation in chronic heart failure patients.

June 24, 2026Journal of the American College of Cardiology

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

Q: What are the key findings of this study?

A single oral dose of sildenafil 25 mg or 50 mg significantly increased flow-mediated vasodilation compared with placebo in patients with chronic heart failure (p < 0.05).

Q: What does this research mean for the field?

A single oral dose of sildenafil (25 mg or 50 mg) significantly increases endothelium-dependent flow-mediated vasodilation compared with placebo in patients with chronic heart failure. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To determine the effects of sildenafil, a type 5 phosphodiesterase inhibitor, on flow-mediated vasodilation in chronic heart failure patients.

View Full Paper

Ask AI

Bookmark

Key result

Single-dose sildenafil 25 or 50 mg increases flow-mediated vasodilation vs placebo in chronic HF.

P<0.05
n=48

Why the study?

Impaired flow-mediated vasodilation in heart failure involves hyporesponsive cGMP-mediated vasorelaxation, but the effect of inhibiting cGMP degradation with sildenafil on flow-mediated dilation was unknown.

Does a single oral dose of sildenafil improve flow-mediated vasodilation in patients with chronic heart failure?

Key Points

To determine the effects of sildenafil, a type 5 phosphodiesterase inhibitor, on flow-mediated vasodilation in chronic heart failure patients.
Measured flow-mediated vasodilation in the brachial artery using high-resolution ultrasound imaging
Conducted a randomized, double-blind trial with 48 patients receiving sildenafil (12.5, 25, or 50 mg) or placebo
Evaluated changes in vasodilation after transient arterial occlusion for 1, 3, and 5 minutes.
Sildenafil 25 mg significantly increased vasodilation responses (3.3%, 3.8%, 4.0%) at 1, 3, and 5 min versus placebo (0.7%, 0.2%, 0.6%) with p < 0.05
Sildenafil 50 mg showed similar improvements (3.7%, 4.1%, 3.9%) compared to placebo across time points, p < 0.05
Patients receiving sildenafil experienced greater endothelium-dependent vasodilation than those receiving placebo.

Study Design

Type

RCT (n=48)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does a single oral dose of sildenafil improve flow-mediated vasodilation in patients with chronic heart failure?

Population

48 patients with chronic heart failure evaluated 1 hour after a single dose of study drug.

Intervention

Single oral dose of sildenafil 12.5, 25, or 50 mg

Comparator

Matching placebo

Outcome

Flow-mediated vasodilation in the brachial artery after release of 1, 3 and 5 min of transient arterial occlusion, measured with high resolution two-dimensional ultrasound imaging 1 h after administrationsurrogate

Main Result

p-value: p=< 0.05

Acute administration of sildenafil 25 mg or 50 mg significantly improves endothelium-dependent, flow-mediated vasodilation in patients with chronic heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support adjunctive PDE5 inhibition in chronic HF; extends mechanistic vasodilation data to randomized clinical populations.

Cite This Study

Katz et al. (2000) conducted an RCT in chronic heart failure (n=48). sildenafil vs. placebo was evaluated on change in flow-mediated vasodilation after release of 1, 3 and 5 min of transient arterial occlusion (p=< 0.05). A single oral dose of sildenafil 25 mg or 50 mg significantly increased flow-mediated vasodilation compared with placebo in patients with chronic heart failure (p < 0.05).

synapsesocial.com/papers/6a3b4ca99889cf2b930e5c49 https://doi.org/10.1016/s0735-1097(00)00790-7

View Full Paper

Ask AI

Bookmark

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider